A Retrospective Analysis Of Adjuvant Therapy For Early Breast Cancer In Cancer Center During The 10 Years

Objective:Collected from the First Hospital of Jilin University Cancer Center 2007.1 to 2016.12 treatment of all patients with early breast cancer basic information,pathological conditions,surgical information,treatment and prognosis and other information,retrospective analysis of my Center within 10 years of patient changes,treatment process changes and prognosis.To analyze the overall DFS and OS,and analysis the differences with the level of domestic and foreign.To analyze the disease characteristics,pathologic characteristics and prognosis of patients with different molecular types,compared with patients disease characteristics of the use of different chemotherapy regimens.Methods:Collected from the First Hospital of Jilin University Cancer Center 2007.1 to 2016.12 treatment of all patients with early breast cancer,according to the inclusion criteria were included in 3013 cases of early breast cancer patients,their basic information on the disease,treatment and prognosis were retrospectively analyzed.To understand the age,pathologic characteristics and prognosis of patients with different molecular types;the characteristics of the disease in patients receiving different chemotherapy regimens;the characteristics of all patients with recurrent metastases.Results:1.The 3 years,5 years,7 years DFS of 1990 patients with a complete follow-up data were 86.9%,75.3%,65.7%.2.The 3 years,5 years,7 years OS of 1990 patients with a complete follow-up data were 99.1%,96.7%,91.8%.3.The prognosis of different molecular types of patients were compared,obtained LuminalA type of DFS than other molecular type of patients is good,followed by luminalB1,basal-like,luminalB2,the worst prognosis of HER-2 positive type.4.LuminalA type,LuminalB1 type of patients with histological grade and tumor volume are better than other molecular types;HER-2 positive type of patients with histological grade,disease staging,tumor volume is worse than other molecular classification.Conclusions:1.The DFS of 3 years,5 years and 7 years were 86.9%,75.3% and 65.7%,and the OS of 3 years,5 years and 7 years were 99.1%,96.7% and 91.8%,which was better than that of domestic and foreign reported.2.Age <35 years old,tumor volume,lymph node metastasis number,HER-2 positive type and basal-like type in patients with high risk of recurrence and metastasis,in the choice of adjuvant therapy,patients can be given a strong treatment program.3.There is a high rate of loss of follow-up,some patients with pathological data loss,to be further verification and supplementation in the future,while improving patient compliance,thereby improving the accuracy of the results.